Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations

被引:15
|
作者
Tamirat, Mahlet Z. [1 ]
Kurppa, Kari J. [2 ]
Elenius, Klaus [2 ,3 ,4 ,5 ]
Johnson, Mark S. [1 ]
机构
[1] Abo Akad Univ, Struct Bioinformat Lab, Biochem, Fac Sci & Engn, Turku 20520, Finland
[2] Univ Turku, Inst Biomed, MediC Res Labs, Turku 20520, Finland
[3] Turku Univ Hosp, Dept Oncol, Turku 20521, Finland
[4] Univ Turku, Turku Biosci Ctr, Turku 20520, Finland
[5] Abo Akad Univ, Turku 20520, Finland
基金
芬兰科学院;
关键词
EGFR tyrosine kinase; exon 20 insertion mutations; non-small cell lung cancer; molecular dynamics simulation; structural biology; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; KINASE DOMAIN; SOMATIC MUTATIONS; CLINICAL-RESPONSE; ERBB RECEPTORS; ACTIVATION; MECHANISM; INSIGHTS; ADENOCARCINOMAS;
D O I
10.3390/cancers13051120
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-small cell lung cancer (NSCLC) is the most common type of lung cancer that claims the lives of many worldwide. Activating mutations occurring on the epidermal growth factor receptor (EGFR) protein have been associated with the pathogenesis of NSCLC, among which exon 20 insertion mutations play a significant role. The objective of this study is to examine the dynamic structural changes occurring on the EGFR protein as a result of two common EGFR exon 20 insertion mutations, V769insASV and D770insNPG. The study further aims to uncover the mechanisms by which the insertion mutations increase kinase activity. Our results suggest that the insertion mutations stabilize structural elements key to maintaining the active EGFR conformation. Furthermore, the insertions disrupt an interaction essential in stabilizing the inactive conformation, which could drive the kinase from an inactive to an active EGFR state. Activating somatic mutations of the epidermal growth factor receptor (EGFR) are frequently implicated in non-small cell lung cancer (NSCLC). While L858R and exon 19 deletion mutations are most prevalent, exon 20 insertions are often observed in NSCLC. Here, we investigated the structural implications of two common EGFR exon 20 insertions in NSCLC, V769insASV and D770insNPG. The active and inactive conformations of wild-type, D770insNPG and V769insASV EGFRs were probed with molecular dynamics simulations to identify local and global alterations that the mutations exert on the EGFR kinase domain, highlighting mechanisms for increased enzymatic activity. In the active conformation, the mutations increase interactions that stabilize the alpha C helix that is essential for EGFR activity. Moreover, the key Lys745-Glu762 salt bridge was more conserved in the insertion mutations. The mutants also preserved the state of the structurally critical aspartate-phenylalanine-glycine (DFG)-motif and regulatory spine (R-spine), which were altered in wild-type EGFR. The insertions altered the structure near the ATP-binding pocket, e.g., the P-loop, which may be a factor for the clinically observed tyrosine kinase inhibitor (TKI) insensitivity by the insertion mutants. The inactive state simulations also showed that the insertions disrupt the Ala767-Arg776 interaction that is key for maintaining the "alpha C-out" inactive conformation, which could consequently fuel the transition from the inactive towards the active EGFR state.
引用
收藏
页码:1 / 21
页数:21
相关论文
共 50 条
  • [31] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Simon Vyse
    Paul H. Huang
    Signal Transduction and Targeted Therapy, 4
  • [32] A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
    Choi, D.
    Jung, H. A.
    Park, S.
    Sun, J-M.
    Ahn, J. S.
    Ahn, M-J.
    Lee, S-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1696 - S1696
  • [33] Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming
    Liu, Haoli
    Qin, Jing
    Qian, Xinyu
    CANCER CONTROL, 2024, 31
  • [34] Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
    Iris K. van Alderwerelt van Rosenburgh
    David M. Lu
    Michael J. Grant
    Steven E. Stayrook
    Manali Phadke
    Zenta Walther
    Sarah B. Goldberg
    Katerina Politi
    Mark A. Lemmon
    Kumar D. Ashtekar
    Yuko Tsutsui
    Nature Communications, 13
  • [35] Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
    van Rosenburgh, Iris K. van Alderwerelt
    Lu, David M.
    Grant, Michael J.
    Stayrook, Steven E.
    Phadke, Manali
    Walther, Zenta
    Goldberg, Sarah B.
    Politi, Katerina
    Lemmon, Mark A.
    Ashtekar, Kumar D.
    Tsutsui, Yuko
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [36] Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients
    Yoon, S.
    Lim, S. M.
    Jung, H. A.
    Kim, K-P.
    Kim, D.
    Jeong, H.
    Lim, S.
    Kim, J.
    Kim, J.
    Patel, D.
    Zhao, X.
    Horsburgh, D.
    Yu, D. Y.
    Kim, J. H.
    Kim, S. Y.
    Lee, D. H.
    ANNALS OF ONCOLOGY, 2022, 33 : S56 - S56
  • [37] Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
    Vasconcelos, Pedro E. N. S.
    Kobayashi, Ikei S.
    Kobayashi, Susumu S.
    Costa, Daniel B.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (03):
  • [38] New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
    David, Gil-Sierra Manuel
    del Pilar, Briceno-Casado Maria
    Cristina, Moreno-Ramos
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 934 - 943
  • [39] Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)
    Piotrowska, Z.
    Nguyen, D.
    Koczywas, M.
    Tchekmedyian, N.
    Clancy, M. S.
    Witter, D.
    Page, A.
    Zawel, L.
    Yu, H. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S862 - S863
  • [40] Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results
    Wang, Mengzhao
    Fan, Yun
    Sun, Meili
    Wang, Yongsheng
    Zhao, Yanqiu
    Jin, Bo
    Hu, Ying
    Han, Zhigang
    Song, Xia
    Liu, Anwen
    Tang, Kejing
    Ding Cuimin
    Liang, Li
    Wu, Lin
    Gao, Junzhen
    Wang, Jianghong
    Cheng, Ying
    Zhou, Jianying
    He, Yong
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)